PXS-4787 是一种特异且有效的泛赖氨酸氧化酶 (lysyl oxidase) 抑制剂,能够消除赖氨酸氧化酶活性,其对 LOX 的抑制 IC50 分别为 2 μM (Bovine LOX)、3.2 μM (rh LOXL1)、0.6 μM (rh LOXL2)、1.4 μM (rh LOXL3) 和 0.2 μM (rh LOXL4)。
产品编号: MS-E49933 CAS No.: 2409963-50-2 分子式: C10H12FNO2S 分子量: 229.27
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PXS-4787 是一种特异且有效的泛赖氨酸氧化酶 (lysyl oxidase) 抑制剂,能够消除赖氨酸氧化酶活性,其对 LOX 的抑制 IC50 分别为 2 μM (Bovine LOX)、3.2 μM (rh LOXL1)、0.6 μM (rh LOXL2)、1.4 μM (rh LOXL3) 和 0.2 μM (rh LOXL4)。

生物实验数据

生物活性 PXS-4787 is a specific and potent pan-lysyl oxidase inhibitor that abolishes lysyl oxidase activity, with IC50 values of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), and 0.2 μM (rh LOXL4) for LOX inhibition.
IC50 & Target

2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4)

体外研究
(In Vitro)

Lysyl oxidases stabilize the main component of scar tissue, collagen, and drive scar stiffness and appearance.
PXS-4787 (0-10 μM; 15 min-4 h) dose- and time-dependently inhibits lysyl oxidase and displays comparable inhibitory activity across species.
PXS-4787 (0-100 μM; 72 h) is well tolerated by primary human dermal fibroblasts, (10 μM; 11 d) reduces collagen formation, deposition and crosslinking in primary human dermal fibroblasts cultured in vitro.
PXS-4787 (10 μM; 48 h) induces differential gene expression in fibroblasts and keratinocytes, including COL1A1, LOX, GAPDH, PGK1.

Immunofluorescence

Cell Line: Primary human dermal fibroblasts cultured in vitro
Concentration: 0, 1, 10 μM
Incubation Time: 11 days
Result: Significantly reduced in the 10 µM treatment group.

RT-PCR

Cell Line: Cultured fibroblasts and keratinocytes (isolated from five different patients)
Concentration: 10 μM
Incubation Time: 48 hours
Result: Resulted four genes with significant differential expression in fibroblasts and two differentially expressed genes in keratinocytes.
体内研究
(In Vivo)

PXS-4787 (3%, oil in water cream; external application; once daily, for 28 days) reduces collagen deposition and cross-linkin in murine models of injury and fibrosis under topical application.
PXS-4787 (3%, oil in water cream; external application; once daily, for 12 weeks) also significantly improves scar appearance without reducing tissue strength in porcine injury models under topical application.

Animal Model: Porcine excision injury model (female Juvenile pigs, 18-20 kg)
Dosage: 3%, oil in water cream; 400 mg cream applied to 16 cm2
Administration: External application; 1, 2 and 3 weeks post-injury; once dailly, for 12 weeks
Result: Improved the appearance of scar in relevant in vivo models, indicative of a targetdriven, as opposed to compound-specific, effect.

化学信息

分子量 229.27
分子式 C10H12FNO2S
CAS No. 2409963-50-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (109.04 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM4.3617 mL21.8083 mL43.6167 mL109.0417 mL
5 mM0.8723 mL4.3617 mL8.7233 mL21.8083 mL
10 mM0.4362 mL2.1808 mL4.3617 mL10.9042 mL
15 mM0.2908 mL1.4539 mL2.9078 mL7.2694 mL
20 mM0.2181 mL1.0904 mL2.1808 mL5.4521 mL
25 mM0.1745 mL0.8723 mL1.7447 mL4.3617 mL
30 mM0.1454 mL0.7269 mL1.4539 mL3.6347 mL
40 mM0.1090 mL0.5452 mL1.0904 mL2.7260 mL
50 mM0.0872 mL0.4362 mL0.8723 mL2.1808 mL
60 mM0.0727 mL0.3635 mL0.7269 mL1.8174 mL
80 mM0.0545 mL0.2726 mL0.5452 mL1.3630 mL
100 mM0.0436 mL0.2181 mL0.4362 mL1.0904 mL
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础